Low-dose aspirin delays an inflammatory tumor progression in vivo in a transgenic mouse model of neuroblastoma

Carcinogenesis

Volumn 34, Issue 5, 2013, Pages 1081-1088

  Carlson, Lena Maria ^a   Rasmuson, Agnes ^a   Idborg, Helena ^a   Segerström, Lova ^a   Jakobsson, Per Johan ^a   Sveinbjörnsson, Baldur ^a,b   Kogner, Per ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b UNIVERSITY OF TROMSØ   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; PROSTAGLANDIN D2; THROMBOXANE A2; TRANSFORMING GROWTH FACTOR BETA;

ABDOMINAL TUMOR; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; DENDRITIC CELL; FLOW CYTOMETRY; INFLAMMATION; INNATE IMMUNITY; LOW DRUG DOSE; MOUSE; NEUROBLASTOMA; NONHUMAN; PRIORITY JOURNAL; TUMOR GROWTH; TUMOR MICROENVIRONMENT; TUMOR VOLUME;

ANIMALS; ASPIRIN; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CYTOKINES; DENDRITIC CELLS; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; HOMOZYGOTE; IMMUNITY, INNATE; INFLAMMATION; MACROPHAGES; MICE; MICE, TRANSGENIC; NEUROBLASTOMA; PROSTAGLANDIN D2; TH2 CELLS; THROMBOXANE A2; TRANSFORMING GROWTH FACTOR BETA;

EID: 84877118822     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgt009     Document Type: Article

References (55)

1. Mantovani,A. et al. (2008) Cancer-related inflammation. Nature, 454, 436-444.
2. Dunn,G.P. et al. (2002) Cancer immunoediting: from immunosurveillance to tumor escape. Nat. Immunol., 3, 991-998.
3. Hanahan,D. et al. (2011) Hallmarks of cancer: the next generation. Cell, 144, 646-674.
4. Thun,M.J. et al. (1991) Aspirin use and reduced risk of fatal colon cancer. N. Engl. J. Med., 325, 1593-1596.
5. Harris,R.E. et al. (2003) Breast cancer and nonsteroidal anti-inflammatory drugs: prospective results from the Women's Health Initiative. Cancer Res, 63, 6096-6101.
6. Rothwell,P.M. et al. (2010) Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomised trials. Lancet, 376, 1741-1750.
7. Rothwell,P.M. et al. (2011) Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials. Lancet, 377, 31-41.
8. Salinas,C.A. et al. (2010) Use of aspirin and other nonsteroidal antiinflammatory medications in relation to prostate cancer risk. Am. J. Epidemiol., 172, 578-590.
9. Cuzick,J. et al. (2009) Aspirin and non-steroidal anti-inflammatory drugs for cancer prevention: an international consensus statement. Lancet Oncol., 10, 501-507.
10. Stiller,C.A. et al. (1992) International variations in the incidence of neuroblastoma. Int. J. Cancer, 52, 538-543.
11. Brodeur,G.M. (2003) Neuroblastoma: biological insights into a clinical enigma. Nat. Rev. Cancer, 3, 203-216.
12. Maris,J.M. (2010) Recent advances in neuroblastoma. N. Engl. J. Med., 362, 2202-2211.
13. Yu,A.L. et al. (2010) Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma. N. Engl. J. Med., 363, 1324-1334.
14. DeNardo,D.G. et al. (2010) Interactions between lymphocytes and myeloid cells regulate pro- versus anti-tumor immunity. Cancer Metastasis Rev., 29, 309-316.
15. Ostrand-Rosenberg,S. (2010) Myeloid-derived suppressor cells: more mechanisms for inhibiting antitumor immunity. Cancer Immunol. Immunother., 59, 1593-1600.
16. Johnsen,J.I. et al. (2004) Cyclooxygenase-2 is expressed in neuroblastoma, and nonsteroidal anti-inflammatory drugs induce apoptosis and inhibit tumor growth in vivo. Cancer Res., 64, 7210-7215.
17. Hansford,L.M. et al. (2004) Mechanisms of embryonal tumor initiation: distinct roles for MycN expression and MYCN amplification. Proc. Natl. Acad. Sci. U.S.A., 101, 12664-12669.
18. Weiss,W.A. et al. (1997) Targeted expression of MYCN causes neuroblastoma in transgenic mice. EMBO J., 16, 2985-2995.
19. Rasmuson,A., et al. (2012) Tumor development, growth characteristics and spectrum of genetic aberrations in the TH-MYCN mouse model of neuroblastoma. PloS One, 7, e51297.
20. Haraguchi,S. et al. (2009) A simple PCR method for rapid genotype analysis of the TH-MYCN transgenic mouse. PLoS ONE, 4, e6902.
21. Roederer,M. (2002) Compensation in flow cytometry. Curr. Protoc. Cytom., Chapter 1, Unit 1.14.
22. Moore,H.C. et al. (2008) Histological profile of tumours from MYCN transgenic mice. J. Clin. Pathol., 61, 1098-1103.
23. Mantovani,A. et al. (2008) Tumour immunity: effector response to tumour and role of the microenvironment. Lancet, 371, 771-783.
24. Chang,Y.C. et al. (2008) Epigenetic control of MHC class II expression in tumor-associated macrophages by decoy receptor 3. Blood, 111, 5054-5063.
25. Fainaru,O. et al. (2010) Tumor growth and angiogenesis are dependent on the presence of immature dendritic cells. FASEB J., 24, 1411-1418.
26. Reagan-Shaw,S. et al. (2008) Dose translation from animal to human studies revisited. FASEB J., 22, 659-661.
27. Nishikawa,H. et al. (2010) Regulatory T cells in tumor immunity. Int. J. Cancer, 127, 759-767.
28. Sica,A. et al. (2008) Macrophage polarization in tumour progression. Semin. Cancer Biol., 18, 349-355.
29. Cole,B.F. et al. (2009) Aspirin for the chemoprevention of colorectal adenomas: meta-analysis of the randomized trials. J. Natl. Cancer Inst., 101, 256-266.
30. Chan,A.T. et al. (2009) Aspirin use and survival after diagnosis of colorectal cancer. JAMA, 302, 649-658.
31. Holmes,M.D. et al. (2010) Aspirin intake and survival after breast cancer. J. Clin. Oncol., 28, 1467-1472.
32. Stark,L.A. et al. (2007) Aspirin activates the NF-kappaB signalling pathway and induces apoptosis in intestinal neoplasia in two in vivo models of human colorectal cancer. Carcinogenesis, 28, 968-976.
33. Johnsen,J.I. et al. (2009) Embryonal neural tumours and cell death. Apoptosis, 14, 424-438.
34. Maris,J.M. et al. (2007) Neuroblastoma. Lancet, 369, 2106-2120.
35. Sarkar,A.K. et al. (2000) Lysis of MYCN-amplified neuroblastoma cells by MYCN peptide-specific cytotoxic T lymphocytes. Cancer Res., 60, 1908-1913.
36. Himoudi,N. et al. (2008) MYCN as a target for cancer immunotherapy. Cancer Immunol. Immunother., 57, 693-700.
37. Wakabayashi,O. et al. (2003) CD4+ T cells in cancer stroma, not CD8+ T cells in cancer cell nests, are associated with favorable prognosis in human non-small cell lung cancers. Cancer Sci., 94, 1003-1009.
38. Curiel,T.J. et al. (2004) Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat. Med., 10, 942-949.
39. DeNardo,D.G. et al. (2009) CD4(+) T cells regulate pulmonary metastasis of mammary carcinomas by enhancing protumor properties of macrophages. Cancer Cell, 16, 91-102.
40. Aspord,C. et al. (2007) Breast cancer instructs dendritic cells to prime interleukin 13-secreting CD4+ T cells that facilitate tumor development. J. Exp. Med., 204, 1037-1047.
41. Merlo,A. et al. (2009) FOXP3 expression and overall survival in breast cancer. J. Clin. Oncol., 27, 1746-1752.
42. Song,L. et al. (2009) Valpha24-invariant NKT cells mediate antitumor activity via killing of tumor-associated macrophages. J. Clin. Invest., 119, 1524-1536.
43. Gabrilovich,D. (2004) Mechanisms and functional significance of tumourinduced dendritic-cell defects. Nat. Rev. Immunol., 4, 941-952.
44. Saccani,A. et al. (2006) p50 nuclear factor-kappaB overexpression in tumor-associated macrophages inhibits M1 inflammatory responses and antitumor resistance. Cancer Res., 66, 11432-11440.
45. Vakkila,J. et al. (2006) Pediatric cancers are infiltrated predominantly by macrophages and contain a paucity of dendritic cells: a major nosologic difference with adult tumors. Clin. Cancer Res., 12(7 Pt 1), 2049-2054.
46. Asgharzadeh,S. et al. (2012) Clinical significance of tumor-associated inflammatory cells in metastatic neuroblastoma. J. Clin. Oncol., 30, 3525-3532.
47. Gowda,M. et al. (2011) Distinct signatures of the immune responses in low risk versus high risk neuroblastoma. J. Transl. Med., 9, 170.
48. Hatzi,E. et al. (2002) N-myc oncogene overexpression down-regulates IL-6; evidence that IL-6 inhibits angiogenesis and suppresses neuroblastoma tumor growth. Oncogene, 21, 3552-3561.
49. Wang,D. et al. (2010) Eicosanoids and cancer. Nat. Rev. Cancer, 10, 181-193.
50. Gupta,R.A. et al. (2003) Cyclooxygenase-1 is overexpressed and promotes angiogenic growth factor production in ovarian cancer. Cancer Res., 63, 906-911.
51. Erovic,B.M. et al. (2008) Strong evidence for up-regulation of cyclooxygenase-1 in head and neck cancer. Eur. J. Clin. Invest., 38, 61-66.
52. Rasmuson,A. et al. (2012) Autocrine prostaglandin E2 signaling promotes tumor cell survival and proliferation in childhood neuroblastoma. PLoS ONE, 7, e29331.
53. Thun,M.J. et al. (2012) The role of aspirin in cancer prevention. Nat. Rev. Clin. Oncol., 9, 259-267.
54. Dovizio,M. et al. (2013) Mode of action of aspirin as a chemopreventive agent. Recent Results Cancer Res., 191, 39-65.
55. Minamino,T. et al. (2012) Thromboxane A(2) receptor signaling promotes liver tissue repair after toxic injury through the enhancement of macrophage recruitment. Toxicol. Appl. Pharmacol., 259, 104-114.